Bayer Logo Bayer Logo Bayer Logo Bayer Logo

Start them off with Adempas

Adempas is the first and only treatment for adult patients with PAH (WHO Group 1)
and inoperable or persistent/recurrent CTEPH (WHO Group 4) after surgery.1*

*Studies establishing effectiveness included predominantly patients with WHO functional class II–III.1

CTEPH=chronic thromboembolic pulmonary hypertension; PAH= pulmonary arterial hypertension; WHO=World Health Organization

PATIENT
ENROLLMENT FORMS

 

Review the patient enrollment process and download the necessary forms.

 

TREATMENT STARTS
WITH SETTING GOALS

 

Get information on prognostic evaluation and risk assessment for your patients with PAH by using the 2015 ESC/ERS Guidelines for every office visit.2

ERS=European Respiratory Society

ESC=European Society of Cardiology

Alt tag

SUPPORT EVERY STEP OF THE WAY

 

With the Aim Patient Support Program, your Adempas patients are covered every step of the way. Here, you can find all of the resources for your patients on their journey. The Aim Patient Support Program is comprised of 3 components: myAim Education and Encouragement, nursing support, and access and financial support.

 

REAL PATIENTS WITH REAL STORIES

 

Throughout treatment, it is important that your PAH and CTEPH patients know they are not alone and can connect with people who are living with their conditions. Read about different patient experiences and become more aware about the struggles of their everyday lives and how Adempas can help.

 
 
MORE IMPORTANT SAFETY INFORMATION LESS IMPORTANT SAFETY INFORMATION

Welcome to the Adempas® website

Adempas® (riociguat) is a soluble guanylate cyclase (sGC) stimulator, the first member of a distinct class of compounds, discovered and developed by Bayer as an oral treatment to target a key molecular mechanism underlying pulmonary hypertension (PH).1,2

Riociguat is approved to treat different types of PH in adults with:

  • inoperable chronic thromboembolic pulmonary hypertension (CTEPH)

  • persistent or recurrent CTEPH after surgery to improve exercise capacity

  • pulmonary arterial hypertension (PAH with WHO functional class II to III, to improve exercise capacity), idiopathic or PAH associated with connective tissue diseases.1-3

 

It is the first drug demonstrating robust and sustained clinical efficacy in two separate PH groups.1,2,11-14

PH is a severe, progressive, and life-threatening disorder of the lungs and heart characterized by elevated blood pressure in the pulmonary arteries, which can lead to right heart failure and death if left untreated.6,7 There are five types of PH; each can affect the patient in a different way and every patient may have a different etiology of PH.8-10

 

Adempas® has a dual mode of action – directly stimulating sGC independently of endogenous nitric oxide (NO) and also facilitating the binding of any remaining endogenous NO to sGC .1,2,15 Patients with CTEPH and PAH are often nitric oxide deficient; this results in sGC being under-stimulated and is associated with a poor prognosis.16-18 For patients with CTEPH and PAH, sGC stimulation is fundamental for providing treatment success and helping to regulate vascular tone, proliferation and inflammation.16-18

Read more
Adempas<sup>®</sup> restores NO-sGC-cGMP pathway and decreases endothelial dysfunction

 

Starting Adempas®

How it works

Disclaimer: Please refer to your country’s specific Adempas® label and prescribing information, as they can differ from the Adempas® Expanded Company Core Data Sheet used to reference this global website.

References

References:
  1. Adempas Prescribing Information. Whippany, NJ. Bayer Pharmaceuticals Inc., 2018.
  2. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37(1):67-119.